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1Introduction
Certain human papillomaviruses (HPVs) are associated 
with certain human tumors. Based on the differential risk 
and association between infections and invasive cervical 
cancer (ICC), HPVs are classified into different risk groups 
[1]. A number of HPVs are considered carcinogenic for 
humans (group 1) or possibly/probably carcinogenic 
(groups 2a and 2b, respectively) and are commonly referred 
to as “high- risk HPVs” [1, 2]. ICC is worldwide the sec-
ond most common cancer affecting women and responsible 
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Abstract
Human papillomavirus (HPV)16 is the most oncogenic human papillomavirus, 
responsible for most papillomavirus- induced anogenital cancers. We have ex-
plored by sequencing and phylogenetic analysis the viral variant lineages present 
in 692 HPV16- monoinfected invasive anogenital cancers from Europe, Asia, 
and Central/South America. We have assessed the contribution of geography 
and anatomy to the differential prevalence of HPV16 variants and to the non-
synonymous E6 T350G polymorphism. Most (68%) of the variance in the dis-
tribution of HPV16 variants was accounted for by the differential abundance 
of the different viral lineages. The most prevalent variant (above 70% prevalence) 
in all regions and in all locations was HPV16_A1- 3, except in Asia, where 
HPV16_A4 predominated in anal cancers. The differential prevalence of variants 
as a function of geographical origin explained 9% of the variance, and the 
differential prevalence of variants as a function of anatomical location accounted 
for less than 3% of the variance. Despite containing similar repertoires of HPV16 
variants, we confirm the worldwide trend of cervical cancers being diagnosed 
significantly earlier than other anogenital cancers (early fifties vs. early sixties). 
Frequencies for alleles in the HPV16 E6 T350G polymorphism were similar 
across anogenital cancers from the same geographical origin. Interestingly, ano-
genital cancers from Central/South America displayed higher 350G allele fre-
quencies also within HPV16_A1- 3 lineage compared with Europe. Our results 
demonstrate ample variation in HPV16 variants prevalence in anogenital cancers, 
which is partly explained by the geographical origin of the sample and only 
marginally explained by the anatomical location of the lesion, suggesting that 
tissue specialization is not essential evolutionary forces shaping HPV16 diversity 
in anogenital cancers.
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for approximately 266,000 deaths per year (http://globocan.
iarc.fr/Default.aspx). Persistent infection by oncogenic 
HPVs is considered a pre- requisite for the development 
of virtually all ICCs [3]. For this reason, the most exten-
sive studies on HPVs have addressed cervical lesions and 
tumors [4]. A similar repertoire of HPVs may also be 
responsible for different fractions of other anogenital 
tumors [5], as viral DNA has been detected in malignant 
proliferations in the penis (33% prevalence) [6, 7], anus 
(88% prevalence) [7, 8], vulva (29% prevalence) [9], and 
vagina (74% prevalence) [10].
Oncogenic potential is not evenly distributed among 
oncogenic HPVs. Instead, HPV prevalence largely differs 
between types and between geographical regions, and the 
probability of progression from a clinically asymptomatic 
cervical infection to ICC is different for different HPVs 
[11, 12]. HPV16 is the most frequently detected HPV in 
all cervical infections, from normal cytology to ICC, in 
all world regions [11, 12]. HPV16 is also the most onco-
genic HPV, responsible for 61% of all ICCs worldwide 
[4] and for even higher fractions of other HPV- associated 
anogenital carcinomas [6, 9, 10]. The biological reasons 
underlying the increased prevalence and oncogenicity of 
HPV16 compared with other closely related viruses, for 
example, the sister viruses HPV31 and HPV35, remain 
unclear [13].
Sequence diversity within HPV types is described in 
terms of viral variants [14]. The best classification for 
HPV16 variants has been proposed by Burk and cowork-
ers, describing four lineages and a number of sublineages 
and applying an alphanumeric code, for example, HPV16_
A4 [15]. Further, a large body of experimental research 
on the differential biological activities of HPV16 variants 
has focused on the E6 gene, especially on the T350G 
polymorphism, corresponding to the L83V amino acid 
substitution in the E6 oncoprotein. The initial literature 
described 350T as the “prototype,” found in the “European” 
HPV16 variant, and the 350G allele as the “nonprototype,” 
found in “non- European” HPV16 variants. However, the 
T350G polymorphism is found in different HPV16 variant 
lineages and is not a specific marker of any of them [16].
Papillomavirus variants are genetically very close, with 
above 98% nucleotide identity [14], but nonetheless HPV16 
variants are suggested to differ in their oncogenic potential 
[17]. Particularly, the E6 T350G polymorphism has been 
associated with differential persistence and risk of progres-
sion to precancerous cervical lesions [17, 18].
The objective of this study was to characterize the viral 
component in a comprehensive set of invasive tumors of 
the cervix, vulva, vagina, penis, and anus, encompassing 
35 countries within three continents. We aimed to analyze 
the differential prevalence of HPV16 variants as well as 
of the intensively studied T350G polymorphism as a 
function of the anatomical location of the lesion, the 
geographical origin of the samples, and the age at cancer 
diagnosis.
Materials and Methods
Samples
Samples analyzed in this study stem from a formalin- fixed 
paraffin- embedded (FFPE) sample repository from the 
Catalan Institute of Oncology (ICO), Barcelona, Spain, 
designed and constructed for the assessment of HPVs 
contribution to a number of anogenital human tumors 
[4, 6, 8–10]. All samples were tested for the presence of 
tumor tissue and for the presence of HPVs DNA using 
the SPF10- LiPA25 protocol, capable of genotyping HPV6, 
11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 
53, 54, 56, 58, 59, 66, 68, 70, and 74 (version 1; Laboratory 
Biomedical Products, Rijswijk, the Netherlands). For this 
study, we selected 711 invasive squamous cell carcinomas 
showing exclusively the presence of HPV16 DNA after 
LiPA25 genotyping. This data set consisted of samples from 
the cervix (n = 170), vulva (n = 128), vagina (n = 121), 
penis (n = 119), and anus (n = 172), spanning 35 dif-
ferent countries within three geographical regions: Europe, 
Central/South America, and Asia (Table S1).
Specimens were received anonymously and allocated a 
unique identification number upon reception, and the 
respective local and ICO ethic committees approved all 
the study protocols.
Identification and selection of the most 
informative regions
The most variable regions in the HPV16 genome were 
identified to maximize sequence diversity and phylogenetic 
signal in the targeted DNA fragments. We retrieved 109 
HPV16 complete genome sequences from GenBank. Coding 
regions were aligned at the amino acid level with Muscle 
3.7 [19] (http://www.ebi.ac.uk/Tools/msa/muscle/), while 
the upstream regulatory region (URR) was aligned at 
nucleotide level. Phylogenetic inference was performed at 
nucleotide level for each alignment, as well as for the 
concatenated full- length aligned genome, under a maxi-
mum likelihood framework using RAxML v7.2.8 [20] 
(http://www.exelixis-lab.org/) and the GTR+Γ4 as substitu-
tion model. Robustness of tree individual nodes was assessed 
by bootstrap resampling analysis, as determined with the 
-autoMRE command [21]. Using the full- length genome 
data and the –J MR_DROP command [22], three rogue 
taxa were identified to show inconsistent positions during 
bootstrapping and were excluded from further analyses. 
The final alignment for the full- length genome comprised 
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7925 nucleotides and 548 distinct alignment patterns (Fig. 
S1). The well- resolved maximum likelihood phylogenetic 
trees obtained were employed to compute tree- based pair- 
wise genetic distances (nucleotide substitutions per site) 
for each pair of taxa and for each genomic region ana-
lyzed, using the RAxML –f x command. Distances were 
then normalized with respect to the genetic distance 
between the corresponding taxa for the complete genome.
PCR and sequencing
DNA was extracted from four 5- μm paraffin slices by 
incubation overnight at 56°C with 250- μL proteinase K 
buffer (10 mg/mL proteinase K, 50 mmol/L Tris- HCl, pH 
8.0) followed by incubation at 95°C for 8 min to inactivate 
proteinase K, and stored at −20°C until use. A 1:10 water 
dilution of this DNA solution was used for downstream 
processing. PCR primers were designed to target- specific 
HPV16 genome regions, so that well- described linage- 
specific polymorphisms were covered by the corresponding 
amplicons (Table S2). We also used primers previously 
designed by Larsson and coworkers [23] to span two posi-
tions in the E6 gene that have been thoroughly analyzed 
in several studies (i.e., nt 131 and 350, reference sequence 
GenBank: NC_001526). All PCR reaction mixtures con-
tained: 0.125 U/μL AmpliTaq Gold® DNA Polymerase (Life 
Technologies, Alcobendas, Spain), 2.0 mmol/L MgCl2, 
0.2 μmol/L deoxynucleotides triphosphate (Life 
Technologies, Alcobendas, Spain), 0.2 μmol/L forward and 
reverse primer (Biolegio , Nijmegen, The Netherlands), 
and 5 μL DNA solution. PCR conditions were 95°C for 
10 min; 40 cycles of 30 sec at 94°C, 30 sec at 58°C, 30 sec 
at 72°C; plus 7- min final extension at 72°C. PCR products 
were Sanger- sequenced at Genoscreen (Lille, France) in 
both strands using four pairs of primers. (Table S2).
Phylogenetic analyses
Phylogenetic relationships of the amplified E6, L2, and 
LCR short fragments were placed in the global context 
of HPV16 genetic variability using an Evolutionary 
Placement Algorithm on RAxML v7.2.8 with the GTR+Γ4 
model [19, 20]. The algorithm provides likelihood weights 
for placing the partial sequences into the different nodes 
in the reference tree, in our case based on the pruned 
full- length genome alignment described above. Sequences 
obtained from our samples were incorporated into the 
reference alignment with MAFFT v7, and their phyloge-
netic placement was individually inferred with the -f v 
command in RAxML [21]. We integrated the results for 
all nodes and used 0.7 as a likelihood cutoff value to 
assign each sample into a specific variant lineage, namely 
A1- 3, A4, B, C, and D (Table S3, Fig. S1). Using the 
0.7 cutoff, 12 samples (1.7%) could only be classified as 
belonging to the A lineage and were subsequently  classified 
as HPV16_A1- 3 using a 0.6 cutoff value (Table S3).
Statistical analyses
A generalized linear model (GLM) with a Poisson distri-
bution for count data and a log- link function was used 
to analyze the relationship between HPV16 variants preva-
lence with the two variables of interest: anatomical location 
and geographical origin. We explored as well the contri-
bution of all double and triple interactions. Significance 
level was set at α value of 0.05. Analyses were performed 
using R in RStudio v0.98.939 (RStudio, Inc.). To cor-
roborate the GLM results, differences in HPV16 variant 
distribution stratifying by anatomical location or by geo-
graphical origin were statistically assessed by means of 
Pearson’s chi- square test and of Fisher’s test, respectively. 
Prevalence ratios (PRs) of HPV16 variants among invasive 
anogenital cancers between Europe and Central/South 
America or Asia were estimated using Poisson multivariate 
regression model with robust variance. The different HPV16 
variant lineages (i.e., A1–3, A4, and D) were used as 
dichotomous variables.
Distribution of the polymorphic site T350G within 
HPV16_A1 variants was assessed by Pearson’s chi- square 
test when stratified by geographical origin and by Fisher’s 
test when stratified by anatomical location. To assess the 
possible differential prevalence of the T|G alleles, we esti-
mated the frequency of this polymorphism within HPV16_
A1- 3 variants for all anatomical locations for samples from 
Europe and Central/South America (Table 3). By focusing 
on the HPV16_A1- 3 variants, we aimed to avoid the pos-
sible different epistatic interactions of the T|G alleles with 
the genetic background of each HPV16 variant, because 
the E6 350 position is also polymorphic T|G in HPV16_B, 
monomorphic T in HPV16_C, and monomorphic G in 
HPV16_D [16]. Asian cases were excluded from this analysis 
due to the small number of samples.
Cancer registry data show that cervical cancers are diag-
nosed earlier than other anogenital cancers associated with 
HPVs [6, 8–10]. Also, cancers caused by HPV16 are diag-
nosed earlier than cancers in the same anatomical location 
caused by other HPVs [4]. To disentangle the effects of 
virus genetics and anatomical location of the lesion on 
the age at diagnosis, we have followed a top- down approach, 
analyzing first age at cancer diagnosis for all HPV- related 
anogenital cancers available from our full clinical data set 
[4, 6, 8, 9], then for all cases exclusively linked to HPV16, 
and finally for all cases exclusively linked to HPV16_A1- 3 
(Fig. 2). For ages at tumor diagnosis, central values were 
estimated with the median, dispersion was estimated with 
the median absolute deviation, and differences were assessed 
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by Wilcoxon–Mann–Whitney test. Bonferroni correction 
for multiple comparisons was used when applicable.
Results
Choice of informative regions and sample 
set description
We identified, in decreasing order, E4, E5, LCR, L2, E2, 
and E6 as the most informative regions in the HPV16 
genome to perform phylogenetic inference (Fig. S2). PCRs 
were designed for each of these six genomic regions, and 
the LCR, L2, and E6 targets rendered the best results in 
terms of amplicon quality and suitability for Sanger sequenc-
ing, as well as for the number of samples that tested 
positive. The final sample set comprised three continents 
(Europe, Central/South America, and Asia) and five ana-
tomical sites (cervix, vulva, vagina, anus, and penis) 
(Table 1; Table S1). From 711 initially suitable amplicons, 
we were able to confidently classify 692 (97.3%) as belong-
ing to HPV16_A1- 3, A4, B, C, or D following an evolu-
tionary placement algorithm (Table S3). Only nine samples 
belonged within the B or C lineages. Given the low numbers 
for both B and C lineages in our sample set, these sequences 
were not included in further analyses.
Geographical origin and anatomical location 
of the HPV16 variant distribution
The association between HPV16_A1- 3, A4, and D variants 
(n = 683) with anatomical location and geographical origin 
was assessed using a GLM analysis. The model that fitted 
best our observations for the complete data set included 
the predictors “Geographical origin,” “Anatomical loca-
tion,” and “Variant” (AIC = 225.88; Table S4). All pre-
dictors and their two- by- two interactions contributed 
significantly to the model (P < 0.0001 in all cases), but 
the triple interaction did not provide additional explana-
tory power (P = 0.36). The GLM analysis fitted very well 
our experimental data, as only <1.4% of all variance in 
HPV16 variant distribution remained unexplained by the 
model (Table S4). In our data set, 14.1% of the global 
variability arose from differential coverage of the three 
geographical regions (n = 342 for Europe, n = 261 for 
Central/South America, and n = 80 for Asia), and only 
1.7% arose from differential coverage of the five anatomi-
cal origins analyzed (n = 163 for cervix, n = 121 for 
vulva, n = 114 for vagina, n = 115 for penis, and n = 170 
for anus). Thus, the GLM approach allowed us to estimate 
and account for possible biases associated with design 
asymmetries in our data. We confirmed further the GLM 
results by estimating prevalence ratios for the different 
HPV16 variants stratifying by geography (Table 2) and 
by using a chi- square test after stratifying for geography 
and a Fisher’s test after stratifying by anatomical location 
of the samples (Table S5).
We estimated that 68.2% of all variation in HPV16 
variants abundance corresponded to actual differences in 
variant prevalence alone (P < 2.2e−16; Table S4). Globally, 
HPV16_A1- 3 was by far the most prevalent variant, with 
an overall prevalence of 95% in Europe, 86% in Central/
South America, and 61% in Asia (F, Table 2). We 
Table 1. Anatomical location and geographical distribution of amplified and classified samples.
Anatomical 
location
Europe Central/South America Asia
Total 
amplified
Total 
classifiedAmplified Classified Amplified Classified Amplified Classified
Cervix 72 70 71 69 27 26 170 165
Vulva 68 68 36 32 24 23 128 123
Vagina 61 60 51 48 10 9 122 117
Penis 74 73 42 40 3 2 119 115
Anal 79 79 72 72 21 21 172 172
Total 354 350 272 261 85 81 711 692
Table 2. Prevalence ratio (PR) of HPV16 variants between Europe and Central/South America or Asia.
Variant Europe (%)
Central/South 
America (%) Asia (%)
Europe vs. Central/South America Europe vs. Asia
PR 95% CI PR 95% CI
A1- 3 324 (94.7) 225 (86.2) 49 (61.3) Ref — Ref —
A4 4 (1.2) 1 (0.4) 26 (32.5) 0.49 0.85–2.84 6.60 4.90–8.88
D 14 (4.1) 35 (13.4) 5 (6.2) 1.75 1.43–2.15 2.00 0.90–4.45
Wald’s test P < 0.001 P < 0.001
5© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
HPV16 Variants in Anogenital CancersS. Nicolás- Párraga et al.
quantified further that 9.0% of all variance in variant 
distribution was explained by differential association of 
viral lineages with geography (P < 2.2e−16; Table S4). 
This variation corresponded to a significant 1.7- fold (95% 
CI: 1.4–2.1) increase of HPV16_D prevalence in Central/
South America and to a significant 6.6- fold (95% CI: 
4.9–8.9) increase of HPV16_A4 prevalence in Asia, in both 
cases compared with Europe (Table 2, see also Fig. 1). 
Finally, 2.8% of all variation in variant distribution cor-
responded to differential association of viral lineages with 
anatomical location (P < 2.1e−05, Table S4, see also Fig. 1). 
This variation stemmed from the increased prevalence of 
HPV16_A4 in vagina and in anus in Asia, where this 
variant prevailed (Table S5, see also Fig. 1). Differences 
remained significant even after excluding data from Asia 
for vagina and penis, both locations with low number of 
cases (Table S5, see also Fig. 1).
HPV16 E6 gene T350G polymorphism
Prevalence for the 350G allele within HPV16_A1- 3 ranged 
between 47% and 59% for Europe and between 59% and 
90% for Central/South America. No differences between 
anatomical locations were observed within each geographical 
region (respectively, P = 0.617 and P = 0.102 for Europe 
and Central/South America). However, HPV16_A1- 3 cases 
from Central/South America showed consistently higher 350G 
allele frequencies compared with Europe, especially for cervi-
cal (P = 0.015) and penile (P < 0.0005) cancers (Table 3).
Age at cancer diagnosis
Cervical cancers showed significantly younger ages at 
diagnosis compared with other anogenital cancers (early 
fifties vs. early sixties, P < 0.0005) regardless of the onco-
genic HPV type or of the HPV16 variant driving the 
cancer (Fig. 2, see also Table S6). Notably, no significant 
differences were observed for age at cancer diagnosis among 
noncervical cancers (Fig. S3, see also Table S7).
Discussion
In this study, we have assessed the HPV16 variant diversity 
in a comprehensive set of invasive tumors of the cervix, 
Figure 1. Distribution of HPV16_A1- 3, A4 and D variants depending on geographical regions and anatomical location. For each combination of 
geography and anatomy, the number of samples is given in parentheses. Values for the contribution of differential variant prevalence (68%), for the 
contribution of geography (9%), and for the contribution of anatomy (3%) have been generated with a generalized linear model. For each anatomical 
location, the result of a chi- square test assessing homogeneity for variant prevalence values between the three geographical origins is provided (e.g., 
for vaginal cancers, the H0 hypothesis of the variant prevalence values being similar in Europe, Central/South America, and Asia is rejected with 
P = 0.004). For each geographical origin, the result of a chi- square test assessing homogeneity for variant prevalence values between the five 
anatomical locations is provided (e.g., for cancers from Central/South America, the null hypothesis of the variant prevalence values being similar in 
cervix, vulva, vagina, anus, and penis is accepted with P = 0.074). HPV16, Human papillomavirus type 16.
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vulva, vagina, penis, and anus, analyzing the HPV16 vari-
ant distribution in 692 invasive squamous cancer samples 
from Europe, Central/South America, and Asia.
We have quantified for the first time the relative con-
tributions of variant differential abundance, geographical 
origin, and anatomical location of the anogenital cancers 
to the observation of differential prevalence distribution 
of HPV16 variants. Our results show that there are no 
large differences between HPV16 lineage prevalence values 
among the anogenital cancers. The most prevalent viral 
lineage was by far HPV16_A1- 3, independently of geo-
graphical origin and anatomical location of the samples, 
with the only exception of anal cancers in Asia, dominated 
by HPV16_A4, albeit based on small numbers. We have 
further estimated the contribution of geography and ana-
tomical location to the observed differential HPV16 variant 
prevalence. The geographical origin of the cancer sample 
explains roughly 9% of all diversity in viral lineage dis-
tribution, and this contribution arises essentially from the 
increased prevalence of HPV16_A4 in samples from Asia 
and of HPV16_D in samples from Central/South America. 
In contrast, the anatomical location of the anogenital 
cancer explains only <3% of the observed diversity in 
viral lineages distribution. Indeed, we have not observed 
significant prevalence differences for HPV16 variants 
between anatomical locations of the anogenital cancers 
within Europe or Central/South America. In Asia, however, 
the higher contribution of HPV16_A4 variant in anogenital 
cancers exhibited a significant prevalence peak for anal 
cancers.
Variant distribution and diversity in HPV16 have mainly 
focused on the uterus cervix [16, 24, 25], but a sound 
description for viral lineages in other anogenital cancers 
sites was still wanting. Here, we have characterized the 
HPV16 variant component in a total of 692 anogenital 
invasive squamous cancers, including more than 550 cases 
from the vulva, vagina, penis, or anus. Our results con-
firm previous results with cervical samples and show 
further that the repertoire of viral HPV16 variants in 
anogenital cancers is largely the same regardless of the 
anatomical location. Consistent with our observations, 
two previous small studies in Northern Europe (HPV 
positive total N = 40; HPV16 positive N = 31) and in 
North America (HPV positive total N = 14; HPV16 
positive N = 9) also reported an increased prevalence 
of HPV16_A1- 3 variants in vulvar cancer (N = 29/31; 
N = 5/9 respectively) [26, 27]. Regarding vaginal cancer, 
the only previous study analyzing HPV16 variants (HPV 
positive total N = 37; HPV16 positive total N = 26) 
showed exclusively the presence of HPV16_A1- 3 variants 
in European samples [26]. For anal cancer, a Canadian 
study (HPV positive total N = 96; HPV16 positive total 
N = 79) reported around 90% prevalence for HPV16_A 
variants [28]. Finally, and concerning viral diversity in 
HPV16- associated penile cancers, an Italian study (HPV 
positive total N = 19; HPV16 positive total N = 18) 
showed above 40% prevalence for both HPV16_A1- 3 
and D variants, along with above 10% minor nonneg-
ligible contribution of HPV16_B variants [29]. However, 
a Mexican series of penile cancer samples (HPV positive 
total N = 67; HPV16 positive total N = 57) showed 
92% prevalence of HPV16_A1- 3 and 8% prevalence of 
HPV16_D [30]. In certain cases, the use in previous 
literature of imprecise naming schemes for HPV16 vari-
ants hampers a proper comparison. To avoid ambiguity, 
we have adhered here to the HPV16 variant terminology 
as standardized by Burk and coworkers [15] and strongly 
encourage further research on HPV variants to stick to 
it. Previous HPV16 variant nomenclatures included poten-
tially misleading geographical references (e.g., “European”) 
or ill- defined arbitrary classifications (e.g., “prototype” 
or “nonprototype”). The use of a geography- based nomen-
clature conveys a message of a close match between 
differential HPV16 variants prevalence and geography, 
which is not justified neither by the best previously 
available data [16] nor by our results presented here.
Table 3. HPV16_A1- 3 variant distribution of the T350G polymorphic site for Europe and Central- South America and for anatomical location.
Anatomical location
Europe (n = 277) Central/South America (n = 182)
F test1N 350G % N 350G %
Cervix 52 29 55.77 42 34 80.95 0.015
Vulva 49 29 59.18 17 10 58.82 1
Vagina 52 30 57.69 42 29 69.05 0.289
Penis 60 28 46.67 30 27 90.00 <0.0005
Anal 64 38 59.38 51 39 76.47 0.072
χ² test2 P = 0.617 P = 0.102
The number of samples (N), the samples with 350G allele (350G), and the percentage for the 350G allele frequencies are represented for each ana-
tomical location for Europe and Central/South America. HPV16, Human papillomavirus type 16.
1Within each anatomical location, differences for the 350G allele frequency in the two geographical origins were assessed using Fisher’s exact test.
2Within each geographical origin, differences for the 350G allele frequency in the different anatomical locations were assessed using chi- square test.
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Minor variations in the viral genome may be responsible 
for important changes regarding increased persistence or 
viral load [36, 37]. In addition, the adaptive host–pathogen 
interaction may further condition the differential probabil-
ity for clearance or for eventual malignization of HPV16 
infections [35, 36]. To tackle this connection between 
viral genotypic diversity and cancer risk, a long- studied 
candidate has been the T350G(L83V) single- nucleotide 
polymorphism in the HPV16 genome [38, 39]. In vitro 
studies have suggested an increased transformation poten-
tial for the 83V allele, especially for the HPV16_D lineage 
[38, 40], although these results may be linked to a specific 
host genetic background [39]. In European populations, 
prospective studies in cervical lesions as well as case–con-
trol studies have also communicated inconsistent results 
regarding the involvement of the T350G polymorphism 
in the persistence and progression to cancer [17, 18, 33, 
41]. To address the question of the differential HPV16_E6 
350G allele frequencies as a function of the geographical 
origin and the anatomical location of the cases, we focused 
exclusively on HPV16_A1- 3 samples from Europe and 
Central/South America. We found that the 350G allele 
frequency did not significantly differ between anatomical 
locations for samples from the same geographical origin. 
In addition, our analysis revealed an increase in 350G 
allele frequency in samples from Central/South America 
compared with samples from Europe, consistent for all 
anatomical locations except for the vulva. This trend is 
in agreement with previous studies reporting an increased 
frequency of the 350G allele in Central/South America 
compared with European populations [31, 32, 33, 34], as 
well as with the minor contribution of this allele in vulvar 
and in vaginal lesions [23, 26].
Finally, we estimated the possible influence of the HPV16 
variant on the age at cancer diagnosis. The rationale behind 
is threefold. First, cancer registry data show that cervical 
cancers are diagnosed earlier than other anogenital cancers 
associated with HPVs (www.hpvcentre.net). Second the 
studies from our group also show that cervical cancers 
caused by more aggressive HPVs, such as HPV16, HPV18, 
or HPV45, are diagnosed earlier than cervical cancers 
caused by other HPVs [4]. Third, the relative contribution 
of the different HPVs varies depending on the anatomical 
location of the cancer. Thus, the observed differences in 
age at diagnosis in HPV- related cancers of different ana-
tomical origin could be linked to specific characteristics 
of the target tissue and/or to the different prevalence of 
the underlying viral agents. Making a coherent picture 
out of all available facts remains, however, a conundrum, 
because the contribution of HPV16 in noncervical cancers 
is higher than in cervical cancer: 61% in cervix [4], 62.9% 
in penis [6], 72.5% in vulva [9], and 75.8% in anus [8]. 
The only exception to this trend is vaginal cancers, 
Figure 2. Age at tumor diagnosis for HPV- positive, HPV16 single infected, 
and HPV16_A1- 3 single infected invasive SCC stratified by cervix, women 
anogenital noncervix (encompassing vagina, vulva, and anus), and men 
anogenital (encompassing anus and penis) samples. For each data set, the 
bar represents the median, the box encompasses the 25–75% percentiles, 
and the whiskers encompass the 95% percentiles. Numbers below each 
graph indicate the median and the range (1.5 × interquartile). Numbers in 
parentheses indicate the sample size for each location. Values for HPV- 
positive and HPV16- positive SCCs have been taken from data sets 
published by de Sanjosé et al. (cervix) [4], Sanjose et al. (vulva) [9], Alemany 
et al. (penis) [6], Alemany et al. (anus) [8], and Alemany et al. (vagina) [10]. 
HPV, human papillomaviruses; SCC, squamous cell carcinomas.
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showing a 57% contribution of HPV16 [10]. One would 
thus expect that the increased contribution of HPV16 in 
noncervical cancers would result in earlier age at diagnosis 
when comparing HPV- related cancers among locations, 
but this is not the case. Our study design offered a unique 
opportunity to disentangle both alternatives and to test 
these hypotheses, as we have gathered a large sample set 
of HPV16- monoinfected cancers of five different anatomi-
cal origins. One explanation could have been that HPV16 
variants show different prevalence in cancers from different 
anatomical locations, but the results communicated here 
suggest that such differences are minor. Remarkably, our 
results for the complete series on HPVs and anogenital 
cancers [4, 6, 8–10] show that differences in age at diag-
nosis remain unchanged between cervical cancers (diag-
nosed in the early fifties) and noncervical cancers 
(diagnosed in the early sixties) when only HPV16 mono-
infections are considered, and even after focusing on 
cancers associated to a single viral lineage, namely the 
most prevalent HPV16_A1- 3. We propose that tissue- 
specific characteristics of the transitional epithelia at the 
uterus cervix may underlie the observed trend in age at 
diagnosis, reflecting an enhanced propensity to infection 
and/or a lower rate of infection clearing, resulting in an 
increased vulnerability to HPV16- driven cervical carcino-
genesis [42]. The anatomy of anal mucosa encompasses 
also the transitional epithelia of a squamous- columnar 
junction, but nevertheless cervical and anal cancers largely 
differ in incidence and prevalence, age at diagnosis as 
well as in the repertoire of HPVs and in the contribution 
of HPV16 to malignization [4, 8]. A particular cellular 
population in the squamous- columnar junction of the 
uterus cervix, the so- called cuboidal cells, which retain 
phenotypic features of embryonic stem cells, is enriched 
among transformed cells located in the uterus cervix, sug-
gesting that they are implicated in cervical neoplasia after 
persistent HPVs infection [43]. However, the microanatomy 
of the anal transformation zone is not identical to that 
of cervical transformation zone: cells in the cervical 
squamous- columnar junction are monolayered, they are 
in direct contact with the basal membrane, and they dis-
play a immunophenotype different tumor [44]. Such 
histochemical differences between cervical and anal trans-
formation zones most likely underlie the large epidemio-
logical differences between cervical and anal HPV- induced 
cancers in terms of incidence, prevalence, and age at 
diagnosis.
Despite the large sample size and the sound molecular 
identification of viral variants, our study suffers from a 
number of limitations. First, we chose to restrict ourselves 
to a very homogeneous study subject, namely invasive 
squamous cell carcinomas containing exclusively HPV16 
DNA. By doing so, we could only recover in our 
repository enough samples from Europe, Central/South 
America, and Asia, as we did not have access to good 
quality samples from the African continent. Indeed, a 
thorough study on the evolution of any human pathogen 
should aim to sample the host–pathogen interaction there 
where the genetic diversity of the host is largest, that is, 
Africa, for humans [45]. Second, we recognize that given 
the variant variability observed in anal samples, the study 
would have benefited from an increase in samples col-
lected from Asia. Third, due to the nature of our study, 
we did not have access to any data regarding patient 
ethnicity and we were thus constrained to proxy the genetic 
background of the patient after the geographical origin 
of the sample. Although the geographical origin of the 
clinical sample is shown to rather reliably reflect the ethnic 
origin of the patient, even in admixed populations such 
as in Central/South America [46], it would have been 
desirable to generate the genetic data from both human 
and virus from the same infection. Finally, we have used 
the broad geographical units defined by the United Nations 
to stratify geography, but we are nevertheless aware that 
these units cover large differences in human genetic diver-
sity that may thus result flattened.
In conclusion, our results provide for the first time a 
sound estimate of the differential contribution of HPV16 
variants to anogenital cancers in Europe, Central/South 
America, and Asia. We identify geographical origin and 
anatomical location as minor factors for explaining the 
differential prevalence of HPV16 variants in anogenital 
cancers. Instead, our results suggest that the increased 
prevalence of HPV16_A1- 3 may reflect a genuinely 
enhanced fitness for this variant to cause cancer. Only a 
large prospective series exploring HPV16 variants preva-
lence on clinically asymptomatic infections, monitoring 
the initial steps of viral colonization of anogenital mucosas 
and following differential viral persistence and accounting 
for the patient’s genetic background, will ultimately provide 
answers about the extent of the differential fitness of these 
viral lineages and will help understand the host interplay 
of the most oncogenic HPV.
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